Document Type


Publication Date



This article has been peer reviewed. It is the authors' final version prior to publication in Critical Care Clinics

Volume 33, Issue 4, October 2017, Pages 897–920.

The published version is available at DOI: 10.1016/j.ccc.2017.06.010. Copyright © Elsevier


The need for extracorporeal membrane oxygenation (ECMO) therapy is a marker of disease severity for which multiple medications are required. The therapy causes physiologic changes that impact drug pharmacokinetics. These changes can lead to exposure-driven decreases in efficacy or increased incidence of side effects. The pharmacokinetic changes are drug specific and largely undefined for most drugs. We review available drug dosing data and provide guidance for use in the ECMO patient population.

Available for download on Monday, October 01, 2018